 |
26 Diseases |  |
58 Trials |
|
58 Trials |  |
4692 News |  |
| «12...51525354555657585960616263» |
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: DRONE: Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Na (clinicaltrials.gov) - Feb 26, 2015
P4, N=202, Not yet recruiting, Sponsor: University Hospital, Strasbourg, France
- | Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
Enrollment open, IO biomarker: Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults (clinicaltrials.gov) - Feb 26, 2015
P4, N=20, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting
- ||||| Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: DolPHIN1: Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study (clinicaltrials.gov) - Feb 23, 2015
P2/3, N=60, Not yet recruiting, Sponsor: University of Liverpool
Not yet recruiting --> Recruiting Initiation date: Jan 2015 --> Apr 2015
- | Enrollment open: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Feb 19, 2015
P3, N=250, Recruiting, Sponsor: University Hospital, Tours
Initiation date: Jan 2015 --> Apr 2015 Not yet recruiting --> Recruiting
- || Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed, Trial primary completion date: DOL-ART: A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (clinicaltrials.gov) - Feb 2, 2015
P=N/A, N=411, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jun 2017
- ||||| Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
New P4 trial, IO biomarker: Renal Integrase Study (clinicaltrials.gov) - Jan 30, 2015
P4, N=60, Not yet recruiting, Sponsor: St Stephens Aids Trust
- ||| Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
Clinical: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=400, Not yet recruiting, Sponsor: ViiV Healthcare
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial, Metastases: Immune Recovery in Advanced , ARV-na (clinicaltrials.gov) - Jan 13, 2015
P4, N=108, Not yet recruiting, Sponsor: Juan A. Arnaiz
- Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: IMPAACT P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents (clinicaltrials.gov) - Jan 9, 2015
P1/2, N=160, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jun 2017 Trial primary completion date: Jan 2016 --> May 2018
- Selzentry (maraviroc) / ViiV Healthcare
Enrollment open, Combination therapy: Switch to Maraviroc + Integrase Inhibitor (clinicaltrials.gov) - Dec 25, 2014
P3, N=30, Recruiting, Sponsor: University of Maryland
Trial primary completion date: Jan 2016 --> May 2018 Not yet recruiting --> Recruiting
- || New P3 trial: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Nov 28, 2014
P3, N=250, Not yet recruiting, Sponsor: University Hospital, Tours
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity (clinicaltrials.gov) - Nov 7, 2014
P4, N=40, Not yet recruiting, Sponsor: St Stephens Aids Trust
- Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Enrollment open, Trial primary completion date: SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers (clinicaltrials.gov) - Nov 5, 2014
P1, N=16, Recruiting, Sponsor: St Stephens Aids Trust
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> May 2015
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change, Trial withdrawal: A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects. (clinicaltrials.gov) - Oct 27, 2014
P1, N=0, Withdrawn, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> May 2015 N=30 --> 0 | Suspended --> Withdrawn
- Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date: Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density (clinicaltrials.gov) - Oct 17, 2014
P3, N=80, Recruiting, Sponsor: Fundacio Lluita Contra la SIDA
N=30 --> 0 | Suspended --> Withdrawn Trial primary completion date: Jul 2015 --> Oct 2015
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: ASPIRE: Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (clinicaltrials.gov) - Oct 15, 2014
P3, N=90, Not yet recruiting, Sponsor: Babafemi Taiwo
- | Tivicay (dolutegravir) / ViiV Healthcare
New P2/3 trial: ODYSSEY: A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART (clinicaltrials.gov) - Oct 11, 2014
P2/3, N=700, Not yet recruiting, Sponsor: PENTA Foundation
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers (clinicaltrials.gov) - Sep 29, 2014
P1, N=15, Completed, Sponsor: ViiV Healthcare
Trial primary completion date: Jul 2015 --> Oct 2015 Active, not recruiting --> Completed
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare
New P2/3 trial: DolPHIN1: Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study (clinicaltrials.gov) - Sep 22, 2014
P2/3, N=60, Not yet recruiting, Sponsor: University of Liverpool
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi, Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial, Combination therapy: DolACT: Dolutegravir Interactions With Artemisinin-based Combination Therapies (clinicaltrials.gov) - Sep 19, 2014
P1, N=46, Not yet recruiting, Sponsor: University of Liverpool
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG) (clinicaltrials.gov) - Sep 4, 2014
P4, N=420, Recruiting, Sponsor: St Stephens Aids Trust
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment (clinicaltrials.gov) - Aug 29, 2014
P3, N=612, Not yet recruiting, Sponsor: ViiV Healthcare
- | Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
New P4 trial, IO biomarker: Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults (clinicaltrials.gov) - Aug 19, 2014
P4, N=20, Not yet recruiting, Sponsor: University of North Carolina, Chapel Hill
- | Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
New P1 trial: SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers (clinicaltrials.gov) - Aug 19, 2014
P1, N=16, Not yet recruiting, Sponsor: St Stephens Aids Trust
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers (clinicaltrials.gov) - Aug 19, 2014
P1, N=15, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial, Adherence: dPEP: The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis (clinicaltrials.gov) - Aug 7, 2014
P4, N=100, Recruiting, Sponsor: Andrew Carr
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers (clinicaltrials.gov) - Jul 30, 2014
P1, N=15, Recruiting, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial: Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers (clinicaltrials.gov) - Jul 10, 2014
P1, N=15, Not yet recruiting, Sponsor: ViiV Healthcare
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection (clinicaltrials.gov) - Jul 1, 2014
P3, N=125, Not yet recruiting, Sponsor: ViiV Healthcare
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects (clinicaltrials.gov) - Jun 4, 2014
P1, N=12, Completed, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects (clinicaltrials.gov) - May 21, 2014
P1, N=30, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date: Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density (clinicaltrials.gov) - Apr 27, 2014
P3, N=80, Recruiting, Sponsor: Fundacio Lluita Contra la SIDA
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Jan 2014
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density (clinicaltrials.gov) - Apr 27, 2014
P3, N=80, Recruiting, Sponsor: Fundacio Lluita Contra la SIDA
Initiation date: Oct 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects (clinicaltrials.gov) - Apr 23, 2014
P1, N=12, Active, not recruiting, Sponsor: ViiV Healthcare
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Tivicay (dolutegravir) / ViiV Healthcare
Enrollment closed: Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects (clinicaltrials.gov) - Apr 9, 2014
P1, N=30, Active, not recruiting, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Tivicay (dolutegravir) / ViiV Healthcare
Enrollment change: AAHIV: Antiretroviral Therapy for Acute and Chronic HIV Infection (clinicaltrials.gov) - Apr 3, 2014
P3, N=150, Recruiting, Sponsor: South East Asia Research Collaboration with Hawaii
Recruiting --> Active, not recruiting N=38 --> 150
- | Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG) (clinicaltrials.gov) - Mar 26, 2014
P4, N=420, Not yet recruiting, Sponsor: St Stephens Aids Trust
- | Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial: Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects (clinicaltrials.gov) - Mar 6, 2014
P1, N=12, Active, not recruiting, Sponsor: ViiV Healthcare
- | Tivicay (dolutegravir) / ViiV Healthcare
New P1 trial: Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects (clinicaltrials.gov) - Feb 13, 2014
P1, N=30, Active, not recruiting, Sponsor: ViiV Healthcare
- Trogarzo (ibalizumab IV) / Theratechnologies, TaiMed Biologics
New P3 trial: Compassionate Use of Ibalizumab for the Treatment of HIV Infection (clinicaltrials.gov) - Jan 5, 2014
P3, N=0, Available, Sponsor: University of Colorado, Denver
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Dolutegravir HIV-1 viral decay and pharmacokinetics in semen in ARV-na (EUDRACT) - Nov 11, 2013
P3, N=15, Ongoing, Sponsor: Unidad de VIH - Servicio de Enfermedades Infecciosas. Hospital de Bellvitge
- || Tivicay (dolutegravir) / ViiV Healthcare
New P3 trial: Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density (clinicaltrials.gov) - Oct 20, 2013
P3, N=80, Recruiting, Sponsor: Fundacio Lluita Contra la SIDA
- Selzentry (maraviroc) / ViiV Healthcare
New P3 trial, Combination therapy: Switch to Maraviroc + Integrase Inhibitor (clinicaltrials.gov) - Jul 9, 2013
P3, N=30, Not yet recruiting, Sponsor: University of Maryland
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects (clinicaltrials.gov) - Jul 2, 2013
P1, N=14, Completed, Sponsor: University of North Carolina, Chapel Hill
N=38 --> 150 Active, not recruiting --> Completed
- Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects (clinicaltrials.gov) - Jul 2, 2013
P1, N=10, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cenicriviroc (TBR-652) / Takeda, AbbVie
Enrollment change: Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam (clinicaltrials.gov) - Jun 24, 2013
P1, N=20, Completed, Sponsor: Tobira Therapeutics, Inc.
Active, not recruiting --> Completed N=40 --> 20
- | cenicriviroc (TBR-652) / Takeda, AbbVie
Trial completion: Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam (clinicaltrials.gov) - Jun 24, 2013
P1, N=20, Completed, Sponsor: Tobira Therapeutics, Inc.
N=40 --> 20 Active, not recruiting --> Completed
- | Tivicay (dolutegravir) / ViiV Healthcare
Trial initiation date, Combination therapy: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects (clinicaltrials.gov) - May 22, 2013
P3, N=13, Active, not recruiting, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Initiation date: Apr 2011 --> Jan 2012
- Tivicay (dolutegravir) / ViiV Healthcare
New P2/3 trial: Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients (clinicaltrials.gov) - Apr 21, 2013
P2/3, N=0, Not yet recruiting, Sponsor: Funda
- | cenicriviroc (TBR-652) / Takeda, AbbVie
New P1 trial: Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam (clinicaltrials.gov) - Apr 7, 2013
P1, N=20, Completed, Sponsor: Tobira Therapeutics, Inc.